Cited by 333Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and ManagementCancer Genomics and Diagnostics

The DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index.

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

Open access

Lee, J.H., Long, G.V., Boyd, S., Lo, S., Menzies, A.M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R.A., Mann, G.J., Kefford, R.F., Carlino, M.S., Rizos, H.·2017·Annals of Oncology

DOI 10.1093/annonc/mdx026

Open this paper in CoChat — free account Open PDF

Abstract

Background Programmed death 1 (PD1) inhibitors are now a foundation of medical management of metastatic melanoma. This study sought to determine whether circulating tumour DNA (ctDNA) provides useful early response and prognostic information.Patients and methods We evaluated the relationship between pre-treatment and early on treatment ctDNA and outcome in melanoma patients treated with PD1 inhibitors alone or in combination with ipilimumab.Results ctDNA was detected in 40/76 patients (53%) at baseline, and correlated with stage, LDH levels, disease volume and ECOG performance. RECIST response was 72% (26/36) in group A (undetectable ctDNA at baseline), 77% (17/22) in group B (elevated ctDNA at baseline but undetectable within 12 weeks of therapy) and 6% (1/18) in group C (elevated ctDNA at baseline and remained elevated during treatment). The median PFS was not reached in groups A and B and was 2.7 months for group C [hazard ratio (HR) 0.09; P < 0.001 for group A versus C, and 0.16; P < 0.001 for group B versus C]. The median OS was not reached for groups A and B and was 9.2 months for group C (HR 0.02; P < 0.001 for group A versus C and 0.14; P < 0.001 for group B versus C). The poor outcome measures associated with group C remained significant in multivariate analysis adjusted for LDH, performance status, tumour stage and disease volume. The predictive value for ctDNA for response was confirmed in a separate validation cohort (n = 29, P < 0.01).Conclusion Longitudinal assessment of ctDNA in metastatic melanoma patients receiving treatment with PD1 inhibitors is an accurate predictor of tumour response, PFS and OS. Patients who had a persistently elevated ctDNA on therapy had a poor prognosis, and this may guide combination and sequencing of subsequent therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdx026

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citation
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citation
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citation
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,725
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Ribas, A., Puzanov, I. J., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,590
Absolute quantification by droplet digital PCR versus analog real-time PCR
Hindson, C. M., Chevillet, J. R., Briggs, H. A., Gallichotte, E. N., Ruf, I. K., Hindson, B. J., Vessella, R. L., & Tewari, M. (2013) · Nature Methods · doi:10.1038/nmeth.2633 · Cited by 1,488

Show all 25 references

Sorted by citations

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
Liquid Biopsy: From Discovery to Clinical Application
Alix‐Panabières, C., & Pantel, K. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1311 · Cited by 1,006
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
Passaro, A., Bakir, M. A., Hamilton, E. G., Diehn, M., André, F., Roy‐Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024) · Cell · doi:10.1016/j.cell.2024.02.041 · Cited by 726
Circulating tumor DNA and liquid biopsy in oncology
Cescon, D. W., Bratman, S. V., Chan, S. M., & Siu, L. L. (2020) · Nature Cancer · doi:10.1038/s43018-020-0043-5 · Cited by 600
Advances in cancer immunotherapy 2019 – latest trends
Krüger, S., Ilmer, M., Kobold, S., Cadilha, B. L., Endres, S., Ormanns, S., Schuebbe, G., Renz, B. W., D’Haese, J. G., Schlößer, H., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1266-0 · Cited by 564
Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells
Keller, L., & Pantel, K. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0180-2 · Cited by 560
Novel patterns of response under immunotherapy
Borcoman, É., Kanjanapan, Y., Champiat, S., Kato, S., Servois, V., Kurzrock, R., Goel, S., Bedard, P. L., & Tourneau, C. L. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz003 · Cited by 529
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Bratman, S. V., Yang, S. Y. C., Iafolla, M. A. J., Liu, Z., Hansen, A. R., Bedard, P. L., Lheureux, S., Spreafico, A., Razak, A. A., Shchegrova, S., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0096-5 · Cited by 487
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Bai, R., Lv, Z., Xu, D., & Cui, J. (2020) · Biomarker Research · doi:10.1186/s40364-020-00209-0 · Cited by 486
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
Goldberg, S. B., Narayan, A., Kole, A. J., Decker, R. H., Teysir, J., Carriero, N. J., Lee, A. Y., Nemati, R., Nath, S. K., Mane, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1341 · Cited by 443
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
Menzies, A. M., Amaria, R. N., Rozeman, E. A., Huang, A. C. C., Tetzlaff, M. T., van de Wiel, B. A., Lo, S., Tarhini, A. A., Burton, E. M., Pennington, T. E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01188-3 · Cited by 452
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy
Lim, S. Y., Lee, J. H., Gide, T. N., Menzies, A. M., Guminski, A., Carlino, M. S., Breen, E. J., Yang, J. Y. H., Ghazanfar, S., Kefford, R. F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2795 · Cited by 381
Tumour burden and efficacy of immune-checkpoint inhibitors
Dall’Olio, F. G., Marabelle, A., Caramella, C., Garcia, C., Aldea, M., Chaput, N., Robert, C., & Besse, B. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00564-3 · Cited by 350
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
Ren, S., Chen, J., Xu, X., Jiang, T., Cheng, Y., Chen, G., Pan, Y., Fang, Y., Wang, Q., Huang, Y., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.018 · Cited by 324
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Anagnostou, V., Forde, P. M., White, J. R., Niknafs, N., Hruban, C., Naidoo, J., Marrone, K. A., Sivakumar, I. K. A., Bruhm, D. C., Rosner, S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1127 · Cited by 322
Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies
Lee, J., Long, G. V., Menzies, A. M., Lo, S., Guminski, A. D., Whitbourne, K., Peranec, M., Scolyer, R. A., Kefford, R. F., Rizos, H., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5332 · Cited by 321
Patterns of Response and Progression to Immunotherapy
Borcoman, É., Nandikolla, A. G., Long, G. V., Goel, S., & Tourneau, C. L. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200643 · Cited by 267
Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology
Bartolomucci, A., de Nóbrega, M., Ferrier, S. T., Dickinson, K., Kaorey, N., Nadeau, A., Castillo, A., & Burnier, J. V. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00876-y · Cited by 301
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
Khair, D. O., Bax, H. J., Mele, S., Crescioli, S., Pellizzari, G., Khiabany, A., Nakamura, M., Harris, R. J. C., French, E., Hoffmann, R. M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00453 · Cited by 252
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
Rosellini, M., Marchetti, A., Mollica, V., Rizzo, A., Santoni, M., & Massari, F. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00676-0 · Cited by 247
Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab
Raja, R. G., Kuziora, M. A., Brohawn, P. Z., Higgs, B. W., Gupta, A. K., Dennis, P. A., & Ranade, K. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0386 · Cited by 240
Cancer immunotherapy: it’s time to better predict patients’ response
Pilard, C., Ancion, M., Delvenne, P., Jérusalem, G., Hubert, P., & Herfs, M. F. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01413-x · Cited by 224
Treatment after progression in the era of immunotherapy
Billan, S., Kaidar‐Person, O., & Gil, Z. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30328-4 · Cited by 205
Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
Hofman, P. M., Heeke, S., Alix‐Panabières, C., & Pantel, K. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz196 · Cited by 205
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
Forschner, A., Battke, F., Hadaschik, D., Schulze, M., Weißgraeber, S., Han, T., Kopp, M., Frick, M., Klumpp, B. D., Tietze, N., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0659-0 · Cited by 215
Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy
Cabel, L., Proudhon, C., Romano, E., Girard, N., Lantz, O. J., Stern, M., Pierga, J., & Bidard, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0074-3 · Cited by 197
Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges
Sanz‐García, E., Stutheit-Zhao, E. Y., Bratman, S. V., & Siu, L. L. (2022) · Science Advances · doi:10.1126/sciadv.abi8618 · Cited by 196
Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
Prelaj, A., Tay, R. Y., Ferrara, R., Chaput, N., Besse, B., & Califano, R. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.002 · Cited by 197
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
Long, G. V., Saw, R. P. M., Lo, S., Nieweg, O. E., Shannon, K. F., Gonzalez, M., Guminski, A. D., Lee, J., Lee, H., Ferguson, P. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30331-6 · Cited by 198
Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
Nakamura, Y. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00119 · Cited by 185
Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study
Tie, J., Wang, Y., Cohen, J. D., Li, L., Hong, W., Christie, M., Wong, H., Kosmider, S., Wong, R., Thomson, B. N. J., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003620 · Cited by 189
Current and Future Clinical Applications of ctDNA in Immuno-Oncology
Stadler, J.-C., Belloum, Y., Deitert, B., Sementsov, M., Heidrich, I., Gebhardt, C., Keller, L., & Pantel, K. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1718 · Cited by 190
Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients
Valpione, S., Gremel, G., Mundra, P. A., Middlehurst, P., Galvani, E., Girotti, M. R., Lee, R. J., Garner, G., Dhomen, N. S., Lorigan, P. C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.029 · Cited by 167
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non–small cell lung cancer (NSCLC)
Ricciuti, B., Jones, G., Severgnini, M., Alessi, J. V., Recondo, G., Lawrence, M., Forshew, T., Lydon, C., Nishino, M., Cheng, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001504 · Cited by 161
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
Chen, X., Wu, X., Wu, H., Gu, Y., Shao, Y. W., Shao, Q., Zhu, F., Li, X., Qian, X., Hu, J. X., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001240 · Cited by 164
Tumor Cell–Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy
Weiss, G. J., Beck, J., Braun, D. P., Bornemann-Kolatzki, K., Barilla, H., Cubello, R., Quan, W., Sangal, A., Khemka, V., Waypa, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0231 · Cited by 149
Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine
Rossi, G., & Ignatiadis, M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3402 · Cited by 146
Evaluation of commercial kits for purification of circulating free DNA
Diefenbach, R. J., Lee, J., Kefford, R. F., & Rizos, H. (2018) · Cancer Genetics · doi:10.1016/j.cancergen.2018.08.005 · Cited by 129
Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy
Hong, X., Sullivan, R. J., Kalinich, M., Kwan, T. T., Giobbie‐Hurder, A., Pan, S., LiCausi, J. A., Milner, J. D., Nieman, L. T., Wittner, B. S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719264115 · Cited by 129
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
Sivapalan, L., Murray, J. C., Canzoniero, J. V., Landon, B., Jackson, J., Scott, S., Lam, V., Levy, B. P., Sausen, M., & Anagnostou, V. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005924 · Cited by 122
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
Seremet, T., Jansen, Y. J. L., Planken, S., Njimi, H., Delaunoy, M., Housni, H. E., Awada, G., Schwarze, J. K., Keyaerts, M., Everaert, H., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2051-8 · Cited by 126
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Dummer, R., Lebbé, C., Atkinson, V. G., Mandalà, M., Nathan, P., Arance, A. M., Richtig, E., Yamazaki, N., Robert, C., Schadendorf, D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1082-2 · Cited by 120
Predictive biomarkers for response to immune checkpoint inhibition
Shum, B., Larkin, J., & Turajlic, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.036 · Cited by 118
Circulating tumour DNA (CtDNA) as a liquid biopsy for melanoma
Calapre, L., Warburton, L., Millward, M., Ziman, M., & Gray, E. S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.030 · Cited by 118
Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition
Basler, L., Gabryś, H. S., Hogan, S. A., Pavic, M., Bogowicz, M., Vuong, D., Tanadini‐Lang, S., Forster, R. E., Kudura, K., Huellner, M. W., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0020 · Cited by 119
Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients
Lee, J., Saw, R. P. M., Thompson, J. F., Lo, S., Spillane, A. J., Shannon, K. F., Stretch, J. R., Howle, J. R., Menzies, A. M., Carlino, M. S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz075 · Cited by 119
Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies
Tie, J., Cohen, J. D., Lo, S., Wang, Y., Li, L., Christie, M., Lee, M., Wong, R., Kosmider, S., Skinner, I., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33312 · Cited by 113
Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer
Oliveira, K. C. D. S., Ramos, I. B., da Silva, J. M. C., Barra, W. F., Riggins, G. J., Palande, V., Pinho, C. T., Frenkel‐Morgenstern, M., Santos, S., de Assumpção, P. P., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0768 · Cited by 108
Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
McEvoy, A. C., Warburton, L., Al‐Ogaili, Z., Celliers, L., Calapre, L., Pereira, M. R., Khattak, M. A., Meniawy, T. M., Millward, M., Ziman, M. R., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4637-6 · Cited by 107
Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors
Kasi, P. M., Fehringer, G., Taniguchi, H., Starling, N., Nakamura, Y., Kotani, D., Powles, T. B., Li, B. T., Pusztai, L., Aushev, V. N., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00181 · Cited by 103
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study
Syeda, M. M., Wiggins, J. M., Corless, B. C., Long, G. V., Flaherty, K. T., Schadendorf, D., Nathan, P. D., Robert, C., Ribas, A., Davies, M. A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30726-9 · Cited by 101
Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?
Yang, M., Forbes, M. E., Bitting, R. L., O’Neill, S. S., Chou, P. C., Topaloĝlu, Ü., Miller, L. D., Hawkins, G. A., Grant, S. C., DeYoung, B. R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx766 · Cited by 99
Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy
Frélaut, M., du Rusquec, P., Moura, A. D., Tourneau, C. L., & Borcoman, É. (2020) · BioDrugs · doi:10.1007/s40259-020-00425-y · Cited by 104
Very early response of circulating tumour–derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non–small cell lung cancer
Iijima, Y., Hirotsu, Y., Amemiya, K., Ooka, Y., Mochizuki, H., Oyama, T., Nakagomi, T., Uchida, Y., Kobayashi, Y., Tsutsui, T., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.004 · Cited by 95
Liquid biomarkers in melanoma: detection and discovery
Lim, S. Y., Lee, J., Diefenbach, R. J., Kefford, R. F., & Rizos, H. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0757-5 · Cited by 99
Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
Lei, Y., Li, X., Huang, Q., Zheng, X., & Liu, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.617335 · Cited by 94
Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis
Petrelli, F., Ardito, R., Merelli, B., Lonati, V., Cabiddu, M., Seghezzi, S., Barni, S., & Ghidini, A. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000520 · Cited by 89
Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors
Lee, J., Menzies, A. M., Carlino, M. S., McEvoy, A. C., Sandhu, S. K., Weppler, A. M., Diefenbach, R. J., Dawson, S., Kefford, R. F., Millward, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3926 · Cited by 87
Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer
Leprieur, E. G., Herbretau, G., Duménil, C., Julié, C., Giraud, V., Labrune, S., Dumoulin, J., Tisserand, J. C., Emile, J., Blons, H., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1424675 · Cited by 85
Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma: A Review
George, S., Rini, B. I., & Hammers, H. J. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4604 · Cited by 84
Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine
Tarhini, A. A., & Kudchadkar, R. R. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.005 · Cited by 84
Unraveling the Wide Spectrum of Melanoma Biomarkers
Revythis, A., Shah, S., Kutka, M., Moschetta, M., Öztürk, M. A., Pappas‐Gogos, G., Ioannidou, E., Sheriff, M., Rassy, E., & Boussios, S. (2021) · Diagnostics · doi:10.3390/diagnostics11081341 · Cited by 80
Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
Li, X., Song, W., Shao, C., Shi, Y., & Han, W. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0086-z · Cited by 79
Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors
Thompson, J. C., Scholes, D. G., Carpenter, E. L., & Aggarwal, C. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02445-1 · Cited by 78
Biomarkers of response to immune checkpoint blockade in cancer treatment
Fujii, T., Naing, A., Rolfo, C. D., & Hajjar, J. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.010 · Cited by 77
Probiotic-Treated Super-Charged NK Cells Efficiently Clear Poorly Differentiated Pancreatic Tumors in Hu-BLT Mice
Kaur, K., Kozłowska, A. K., Topchyan, P., Ko, M.-W., Ohanian, N., Chiang, J., Cook, J., Maung, P. O., Park, S., Cacalano, N. A., et al. (2019) · Cancers · doi:10.3390/cancers12010063 · Cited by 71
Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients
Eroglu, Z., Krinshpun, S., Kalashnikova, E. V., Sudhaman, S., Topcu, T. O., Nichols, M., Martin, J., Bui, K. M., Palsuledesai, C. C., Malhotra, M., et al. (2023) · Cancer · doi:10.1002/cncr.34716 · Cited by 76
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
Pavlick, A. C., Ariyan, C. E., Buchbinder, E. I., Davar, D., Gibney, G. T., Hamid, O., Hieken, T. J., Izar, B., Johnson, D. B., Kulkarni, R. P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006947 · Cited by 74
Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib
Oh, C. R., Kong, S., Im, H.-S., Kim, H. J., Kim, M. K., Yoon, K., Cho, E., Jang, J.-H., Lee, J., Kang, J., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5483-x · Cited by 66
Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy
Marsavela, G., Lee, J., Calapre, L., Wong, S. Q., Pereira, M. R., McEvoy, A. C., Reid, A. L., Robinson, C., Warburton, L., Abed, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2251 · Cited by 66
Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non‐Small Cell Lung Cancer
Jia, Q., Chiu, L.-T., Wu, S., Bai, J., Peng, L., Zheng, L., Zang, R., Li, X., Yuan, B., Gao, Y., et al. (2020) · Advanced Science · doi:10.1002/advs.201903410 · Cited by 64
Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors
Heidrich, I., Deitert, B., Werner, S., & Pantel, K. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10075-x · Cited by 65
Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients
Marczynski, G. T., Laus, A. C., dos Reis, M. B., Reis, R. M., & Vazquez, V. D. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-75792-1 · Cited by 67
Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells
Aya‐Bonilla, C., Morici, M., Hong, X., McEvoy, A. C., Sullivan, R. J., Freeman, J. B., Calapre, L., Khattak, M. A., Meniawy, T. M., Millward, M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0750-9 · Cited by 64
Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy
Herbreteau, G., Vallée, A., Knol, A., Théoleyre, S., Quereux, G., Varey, É., Khammari, A., Dréno, B., & Denis, M. G. (2018) · Oncotarget · doi:10.18632/oncotarget.25404 · Cited by 60
Malignant Melanoma: Diagnostic and Management Update
Knackstedt, T., Knackstedt, R. W., Couto, R. A., & Gastman, B. (2018) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000004571 · Cited by 62
Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma
Fan, K., Ritter, C., Nghiem, P., Blom, A., Verhaegen, M. E., Dlugosz, A. A., Ødum, N., Woetmann, A., Tothill, R. W., Hicks, R. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1184 · Cited by 62
Emerging biomarkers for cancer immunotherapy in melanoma
Axelrod, M. L., Johnson, D. B., & Balko, J. M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.004 · Cited by 58
Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review
Al-Showbaki, L., Wilson, B. E., Tamimi, F., Moltó, C., Mittal, A., Cescon, D. W., & Amir, E. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005854 · Cited by 56
Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma
McEvoy, A. C., Calapre, L., Pereira, M. R., Giardina, T. M., Robinson, C., Khattak, M. A., Meniawy, T. M., Pritchard, A. L., Hayward, N. K., Amanuel, B., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20354 · Cited by 56
Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma
Váraljai, R., Wistuba‐Hamprecht, K., Seremet, T., Diaz, J. M. S., Nsengimana, J., Sucker, A., Griewank, K., Placke, J., Horn, P., Neuhoff, N. V., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00229 · Cited by 53
Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis
Gracie, L., Pan, Y., Atenafu, E. G., Ward, D. G., Teng, M. S. L., Pallan, L., Stevens, N. M., & Khoja, L. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.019 · Cited by 51
Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response
Valenti, F., Falcone, I., Ungania, S., Desiderio, F., Giacomini, P., Bazzichetto, C., Conciatori, F., Gallo, E., Cognetti, F., Ciliberto, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083837 · Cited by 52
Locus‐specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma
Calapre, L., Giardina, T. M., Robinson, C., Reid, A. L., Al‐Ogaili, Z., Pereira, M. R., McEvoy, A. C., Warburton, L., Hayward, N. K., Khattak, M. A., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12391 · Cited by 50
Immune checkpoint: The novel target for antitumor therapy
Jiang, X., Liu, G., Li, Y., & Pan, Y. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.12.004 · Cited by 48
Emerging Biomarkers in Cutaneous Melanoma
Eisenstein, A. S., Gonzalez, E. C., Raghunathan, R., Xu, X., Wu, M., McLean, E. O., McGee, J. S., Ryu, B., & Alani, R. M. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0318-z · Cited by 48
Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma
Braune, J., Keller, L., Schiller, F., Graf, E., Rafei-Shamsabadi, D. A., Wehrle, J., Follo, M., Philipp, U., Hussung, S., Pfeifer, D., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00174 · Cited by 52
Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients’ treatment
Onesti, C. E., Frères, P., & Jérusalem, G. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.47 · Cited by 46
Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives
Malissen, N., & Grob, J. (2018) · Drugs · doi:10.1007/s40265-018-0945-z · Cited by 46
Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay
Lyu, N., Rajendran, V. K., Diefenbach, R. J., Charles, K. A., Clarke, S. J., Engel, A. F., Sydney 1000 Colorectal Cancer Study Investigators*, Rizos, H., Molloy, M. P., & Wang, Y. (2020) · Nanotheranostics · doi:10.7150/ntno.48905 · Cited by 44
Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring
Kamińska, P., Buszka, K., Zabel, M., Nowicki, M. O., Alix‐Panabières, C., & Budna, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189714 · Cited by 44
The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Wang, H., Zhou, F., Qiao, M., Li, X., Zhao, C., Cheng, L., Chen, X., & Zhou, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.671874 · Cited by 42
Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients
Lim, S. Y., Lee, J., Welsh, S. J., Ahn, S. B., Breen, E. J., Khan, A., Carlino, M. S., Menzies, A. M., Kefford, R. F., Scolyer, R. A., et al. (2017) · Biomarker Research · doi:10.1186/s40364-017-0112-9 · Cited by 42
From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real‐world setting
Rowe, S. P., Luber, B. S., Makell, M., Brothers, P., Santmyer, J., Schollenberger, M. D., Quinn, H., Edelstein, D. L., Jones, F. S., Bleich, K. B., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12373 · Cited by 42
Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.
Irizarry-Alvarado, J. M., Dwyer, J. P., Brumble, L. M., Álvarez, S., & Mendez, J. (2009) · PubMed · Cited by 39
Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management
Sacco, A., Forgione, L., Carotenuto, M., Luca, A. D., Ascierto, P. A., Botti, G., & Normanno, N. (2020) · Cancers · doi:10.3390/cancers12102914 · Cited by 40
Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma
Kim, Y. J., Kang, Y., Kim, J. S., Sung, H. H., Jeon, H. G., Jeong, B. C., Seo, S. I., Jeon, S. S., Lee, H. M., Park, D., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-85099-4 · Cited by 39
Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer
Shang, M., Chang, C., Pei, Y., Guan, Y., Chang, J., & Li, H. (2018) · Journal of Cancer · doi:10.7150/jca.28458 · Cited by 37
Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients
Gorges, K., Wiltfang, L., Gorges, T. M., Sartori, A., Hildebrandt, L., Keller, L., Volkmer, B., Peine, S., Babayan, A., Moll, I., et al. (2019) · Cancers · doi:10.3390/cancers11111685 · Cited by 38

Authors: Lee, J. H., Long, G. V., Boyd, S., Lo, S., Menzies, A. M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R. A., Mann, G. J., Kefford, R. F., Carlino, M. S., & Rizos, H.
Affiliations: The University of Sydney (AU)
Macquarie University (AU)
Melanoma Institute Australia (AU)
Royal Prince Alfred Hospital (AU)
Corresponding author: Rizos, H.
ORCID: Lee, J.H.
Long, G.V.
Lo, S.
Menzies, A.M.
Guminski, A.
Jakrot, V.
Scolyer, R.A.
Mann, G.J.
Kefford, R.F.
Carlino, M.S.
Rizos, H.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2017-05
Volume: 28
Issue: 5
Pages: 1130-1136
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1093/annonc/mdx026
OpenAlex: W2588078993
Cited by: 333
References: 25
Citations by year: 2026: 22 · 2025: 21 · 2024: 16 · 2023: 52 · 2022: 28 · 2021: 51 · 2020: 48 · 2019: 43 · 2018: 39 · 2017: 12
FWCI: 17.23
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 917 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: National Health and Medical Research Council (1093017 and 1130423)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: circulating tumor DNA, metastatic melanoma, PD-1 inhibitors, ipilimumab, treatment response prediction, prognostic factors, progression-free survival, overall survival, longitudinal ctDNA monitoring, immune checkpoint inhibitors
MeSH terms: Circulating Tumor DNA, Ipilimumab, Aged, Antibodies, Anti-Idiotypic, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Biomarkers, Tumor, Neoplasms, Second Primary, Disease-Free Survival, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks